TG Therapeutics (NASDAQ:TGTX) Sets New 52-Week High at $9.73

TG Therapeutics Inc (NASDAQ:TGTX)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $9.73 and last traded at $9.18, with a volume of 3180263 shares. The stock had previously closed at $7.12.

A number of research firms have recently issued reports on TGTX. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a research report on Tuesday. ValuEngine lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. B. Riley initiated coverage on TG Therapeutics in a research report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. TG Therapeutics has an average rating of “Buy” and a consensus target price of $12.95.

The company has a debt-to-equity ratio of 2.77, a current ratio of 1.00 and a quick ratio of 1.00. The firm has a 50-day moving average of $7.44 and a two-hundred day moving average of $6.97.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.33). TG Therapeutics had a negative return on equity of 2,411.79% and a negative net margin of 123,130.93%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. As a group, analysts anticipate that TG Therapeutics Inc will post -1.96 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in TGTX. SG Americas Securities LLC lifted its stake in TG Therapeutics by 5.0% during the second quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 1,481 shares in the last quarter. Aperio Group LLC acquired a new position in TG Therapeutics during the second quarter worth $32,000. Cutter & CO Brokerage Inc. acquired a new position in TG Therapeutics during the second quarter worth $176,000. Swiss National Bank lifted its stake in TG Therapeutics by 19.9% during the second quarter. Swiss National Bank now owns 140,500 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 23,300 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in TG Therapeutics by 12.7% during the second quarter. JPMorgan Chase & Co. now owns 258,296 shares of the biopharmaceutical company’s stock worth $2,061,000 after purchasing an additional 29,098 shares in the last quarter. Institutional investors own 48.64% of the company’s stock.

TG Therapeutics Company Profile (NASDAQ:TGTX)

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

See Also: 52 Week Highs

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.